A 66-year-old man with a history of coronary artery disease was evaluated due to ventricular tachycardic (VT) storm. The patient continued to have frequent recurrences of VT despite treatment with amiodarone and lidocaine. Since the ventricular arrhythmia could be related to myocardial ischemia related to a chronic total occlusion (CTO) of the right coronary artery, the patient underwent successful percutaneous coronary intervention of the CTO, followed by implantable cardioverter defibrillator implantation. He had no further episodes of VT during his hospital stay. After 9 months of follow-up, he had no further chest pain or clinically apparent recurrent ischemia. Interrogation of his defibrillator has shown brief nonsustained episodes of ventricular tachycardia, but the patient has not required delivery of a shock. The temporal association between treatment of the CTO and resolution of the VT, as well as the lack of recurrence of sustained VT, suggest a causative link between underlying ischemia produced by a chronically occluded coronary artery and provocation of VT and lend supportive evidence to this treatment approach. P atients with chronic total occlusions (CTOs) of the coronary arteries most commonly present with angina pectoris or exertional dyspnea. Th e role of a CTO in arrhythmogenesis is less clear. Advanced techniques now exist allowing percutaneous treatment of complex CTOs, which can not only improve patient symptoms but may also decrease arrhythmia.
CASE DESCRIPTION
A 66-year-old man with a history of coronary artery disease, for which he had undergone coronary artery bypass grafting 12 years previously, was transferred to our tertiary care facility due to ventricular tachycardic storm. He had been well until 4 days prior to admission, at which time he presented to an outside facility with syncope. He had spontaneous recovery of consciousness prior to the arrival of emergency medical services. Continuous telemetric monitoring showed no ventricular arrhythmia, an echocardiogram showed normal left ventricular size and normal systolic function, and a nuclear myocardial perfusion study showed a large perfusion defect involving the inferior and inferolateral walls, a mixture of infarction and ischemia. Th e etiology of syncope was unclear.
Two days after dismissal, he had acute onset of substernal chest discomfort that radiated toward his right shoulder and back. Emergency medical services was again summoned; en route to the hospital he was documented to have multiple episodes of ventricular tachycardia (VT) managed with direct current cardioversion and subsequent initiation of intravenous amiodarone. Th e patient continued to have frequent recurrences of VT (Figure 1a) , which prompted the additional initiation of intravenous lidocaine (bolus and drip). Baseline laboratory results revealed normal serum potassium, magnesium, calcium, and phosphorus. Initial serum troponin levels were below assay limit but eventually climbed to a peak of 3.35 ng/mL (abnormal > 0.10 ng/mL). Baseline electrocardiogram (Figure 1b) showed sinus tachycardia, a right bundle branch block, and Q waves in leads II, III, and aVF, with mild diff use ST segment depression. Cardiac catheterization revealed a patent left internal mammary artery to his left anterior descending artery and two occluded saphenous vein grafts, one previously anastomosed to the second obtuse marginal branch and one to the distal right coronary artery (RCA). Th e native mid left circumfl ex and proximal RCA were occluded. Th e occluded RCA was unchanged compared to the description of a prior angiogram done 5 years previously (Figures 2a, 2b) .
Th e decision was made that the ventricular arrhythmia could be related to myocardial ischemia related to the CTOs. Due to the fi ndings of thinning and akinesis of the lateral wall, as well as the angiographic nature of the two CTOs, percutaneous coronary intervention (PCI) of the CTO of the RCA was planned, and the patient was transferred to our tertiary care center.
Th e patient underwent successful PCI of the CTO. As all collaterals to the distal RCA were arising from the proximal RCA, a single 8F, AL1 guide was used to cannulate the RCA. Th e proximal "cap" was found to be hard, impenetrable to our workhorse wire, with no evidence of microchannels based on probing with a tapered-tip, polymer-coated wire (Fielder XT, Abbott Vascular, Temecula, CA). Th e proximal cap was able Ventricular tachycardic storm with a chronic total coronary artery occlusion treated with percutaneous coronary intervention (Figure 2f ) . Th e patient received intravenous unfractionated heparin during the case, with a target activated clotting time of 250 to 300 seconds. He had been loaded with clopidogrel 600 mg a few hours prior to the procedure.
Subsequently, he had no further episodes of VT during his hospital stay. His intravenous amiodarone and lidocaine were discontinued approximately 12 hours after the procedure. Serial troponin I peaked at 3.35 ng/mL. An implantable cardioverter defi brillator (ICD) was placed the following day without complication. He was observed another 24 hours in the hospital, during which no further ventricular arrhythmia was seen, and no complications from either the PCI or ICD implantation to be penetrated using a Confi anza Pro 12 (Abbott Vascular, Temecula, CA) with support of a FineCross (Terumo Medical Somerset, NJ) microcatheter. Once engaged in the occlusion, the Confi anza Pro 12 was exchanged for a Pilot 200 (Abbott Vascular, Temecula, CA), which was able to be advanced into a medium-sized right ventricular marginal branch beyond the occlusion (Figure 2c) . A small channel was made in the occlusion with an Apex 1.5 mm balloon (Boston Scientifi c, Natick, MA), after which the pilot wire was able to be moved into the main RCA channel. Angiography confi rmed intraluminal placement (Figures 2d, 2e) . Th e pilot wire was exchanged for a standard workhorse wire (Luge, Boston Scientifi c, Natick, MA), and further angioplasty was performed culminating in placement of a single 2.75 × 28 Promus element drug-eluting stent (Boston Scientifi c, Natick, MA), which was postdilated with a were present. He was initially discharged on oral amiodarone, but this was stopped shortly after discharge due to concern for potential side eff ects.
At 9-month follow-up, the patient had no further chest pain or clinically apparent recurrent ischemia. ICD interrogation has shown brief nonsustained episodes of VT, but he has not required delivery of a shock.
DISCUSSION
CTOs can lead to a number of clinical sequelae. Th e most common scenario that prompts revascularization is the presence of stable, exertional angina pectoris. Many present with dyspnea and decreased exercise tolerance (often attributed to other causes including aging), and reports have documented a higher incidence of left ventricular dysfunction, ventricular arrhythmia, and cardiac death among patients with a CTO. Additionally, retrospective studies of treatment of CTOs have suggested improvements not just in anginal class, but in ventricular performance (1, 2) , exercise tolerance (3), tolerance of future ischemic events (4), and even mortality (5) (6) (7) (8) . While the retrospective nature of these trials limits the conclusions, they nonetheless suggest that treatment of CTOs may benefi t the patient beyond simply a reduction in angina.
Elegant studies have shown that virtually all CTOs are ischemic when tested by fractional fl ow reserve, regardless of the maturity of collateral channels (9, 10) . Most are ischemic at rest, even in the absence of vasodilators and hyperemia. Furthermore, there is supportive evidence that a CTO not only produces ischemia in the zone supplied by the CTO, but may also provoke ischemia in the territory of donor collateral vessels (11) .
Animal studies have shown that hibernating myocardium can be a focus of ventricular arrhythmia and sudden cardiac death, even in the absence of acute or prior myocardial infarction. Furthermore, even though adaptations may have occurred that allow for normal myocardial functioning, the potential for life-threatening arrhythmia still exists (12) .
Prior studies have explored the link between CTOs and ventricular arrhythmia. Nombela-Franco et al studied 162 patients who had received an ICD to prevent sudden cardiac death (13) . Among that group, 44% had at least one CTO. Over a 26-month period, appropriate device therapy was delivered to 18% of the patients. Th e presence of a CTO was found to be associated with higher rates of ventricular arrhythmia and death and was independently associated with appropriate ICD therapy (hazard ratio 3.5). In conclusion, percutaneous treatment of CTOs may lead not only to relief of angina and dyspnea, but also to resolution of ventricular arrhythmia by minimizing underlying ischemia.
